Top

Published in:

Open Access 01-09-2020 | SARS-CoV-2 | Commentary

ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?

Authors: Vincenzo M. Monda, Francesca Porcellati, Felice Strollo, Sandro Gentile

Published in: Diabetes Therapy | Issue 9/2020

Excerpt

Recently it has been hypothesized that DPP4 inhibitors can have a beneficial effect on SARS-CoV-2 infection through immunoregulating activity.

Experimental study on streptozotocin-treated rats showed that liraglutide was able to stimulate the expression of pulmonary angiotensin converting enzyme 2 (ACE2) and angiotensin (1–7).

Liraglutide modulated different elements of the renin angiotensin system (RAS), significantly increasing ACE2 and Mas receptor (MasR) mRNA expression in pup lungs from food-restricted mothers.

Some action mechanisms support the hypothesis of a protective action of GLP-1R agonists, capable of mitigating a more serious clinical course among SARS-CoV-2-infected individuals with T2DM.

…

Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. https://doi.org/10.1016/S0140-6736(20)30251-8.CrossRefPubMedPubMedCentral

Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8(suppl):S9–14. https://doi.org/10.1046/j.1440-1843.2003.00518.x.CrossRefPubMedPubMedCentral

WHO Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/. Accessed 16 Jan 2018.

Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–4. https://doi.org/10.1038/nature12005.CrossRefPubMedPubMedCentral

Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(5):262–9. https://doi.org/10.1038/nrendo.2009.48.CrossRefPubMed

Martin JH, Deacon CF, Gorrell MD, Prins JB. Incretin-based therapies—review of the physiology, pharmacology and emerging clinical experience. Intern Med J. 2011;41(4):299–307. https://doi.org/10.1111/j.1445-5994.2011.02439.x.CrossRefPubMed

Hedrington MS, Davis SN. Oral semaglutide for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2019;20(2):133–41. https://doi.org/10.1080/14656566.2018.155225.CrossRefPubMed

Iacobellis G. COVID-19 and diabetes: can DPP-IV inhibition play a role? Diabetes Res Clin Pract. 2020;162:108125. https://doi.org/10.1016/j.diabres.2020.108125.CrossRefPubMedPubMedCentral

Tianru J. Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment. Acta Pharm Sin B. 2020. https://doi.org/10.1016/j.apsb.2020.05.006.CrossRef

10.

Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020;41(3):bnaa011. https://doi.org/10.1210/endrev/bnaa011.CrossRefPubMed

11.

Mirabelli M, Chiefari E, Puccio L, Foti DP, Brunetti A. Potential benefits and harms of novel antidiabetic drugs during COVID-19 crisis. Int J Environ Res Public Health. 2020;17(10):3664. https://doi.org/10.3390/ijerph17103664.CrossRefPubMedCentral

12.

Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642. https://doi.org/10.1155/2016/3094642.CrossRefPubMedPubMedCentral

13.

Romaní-Pérez M, Outeiriño-Iglesias V, Moya CM, et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology. 2015;156(10):3559–69. https://doi.org/10.1210/en.2014-1685.CrossRefPubMed

14.

Fandiño J, Vaz AA, Toba L, et al. Liraglutide enhances the activity of the ACE-2/Ang(1–7)/Mas receptor pathway in lungs of male pups from food-restricted mothers and prevents the reduction of SP-A. Int J Endocrinol. 2018;2018:6920620. https://doi.org/10.1155/2018/6920620.CrossRefPubMedPubMedCentral

15.

Wösten-van Asperen RM, Lutter R, Specht PA, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. J Pathol. 2011;225(4):618–27. https://doi.org/10.1002/path.2987.CrossRefPubMed

16.

Kuba K, Imai Y, Rao S, Jiang C, Penninger JM. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. J Mol Med (Berl). 2006;84(10):814–20. https://doi.org/10.1007/s00109-006-0094-9.CrossRef

17.

Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020. https://doi.org/10.1016/j.ejim.2020.04.037.CrossRefPubMedPubMedCentral

18.

Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1–7). Physiol Rev. 2018;98(1):505–53. https://doi.org/10.1152/physrev.00023.2016.CrossRefPubMed

19.

Fang C, Stavrou E, Schmaier AA, et al. Angiotensin 1–7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood. 2013;121(15):3023–32. https://doi.org/10.1182/blood-2012-09-459156(published correction appears in Blood. 2014 Mar 6;123(10):1622).CrossRefPubMedPubMedCentral

20.

Celi A, Cianchetti S, Dell'Omo G, Pedrinelli R. Angiotensin II, tissue factor and the thrombotic paradox of hypertension. Expert Rev Cardiovasc Ther. 2010;8(12):1723–9. https://doi.org/10.1586/erc.10.161.CrossRefPubMed

21.

Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247–57. https://doi.org/10.1002/emmm.201000080.CrossRefPubMedPubMedCentral

22.

Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–74. https://doi.org/10.1161/CIRCRESAHA.120.317015.CrossRefPubMed

23.

Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98. https://doi.org/10.1007/s00134-020-06062-x.CrossRefPubMedPubMedCentral

24.

Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5(1):58–68.CrossRefPubMed

25.

Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487(7408):477–81. https://doi.org/10.1038/nature11228.CrossRefPubMedPubMedCentral

26.

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–90. https://doi.org/10.1007/s00134-020-05985-9.CrossRefPubMedPubMedCentral

27.

Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020. https://doi.org/10.1002/ddr.21656.CrossRefPubMedPubMedCentral

28.

Benicky J, Sánchez-Lemus E, Pavel J, Saavedra JM. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol. 2009;29(6–7):781–92. https://doi.org/10.1007/s10571-009-9368-4.CrossRefPubMed

29.

Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85. https://doi.org/10.1016/S2213-8587(19)30249-9.CrossRefPubMed

30.

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–8. https://doi.org/10.1016/S0140-6736(19)31150-X.CrossRefPubMed

Title: ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?
Authors: Vincenzo M. Monda
Francesca Porcellati
Felice Strollo
Sandro Gentile
Publication date: 01-09-2020
Publisher: Springer Healthcare
Keywords: SARS-CoV-2
Acute Respiratory Distress-Syndrome
COVID-19
Liraglutide
Incretin Mimetics
Incretin Mimetics
Published in: Diabetes Therapy / Issue 9/2020
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-020-00898-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2020

Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis

Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies

Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials

Burden of Diabetes and Prediabetes in Nepal: A Systematic Review and Meta-Analysis

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials